Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel Free WGS Stock Alerts

GeneDx (WGS) Financials

GeneDx logo
$85.26 +1.30 (+1.55%)
Closing price 04:00 PM Eastern
Extended Trading
$85.50 +0.24 (+0.28%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for GeneDx

Annual Income Statements for GeneDx

This table shows GeneDx's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -33 -241 -245 -549 -176 -52 -21
Consolidated Net Income / (Loss)		 -30 -241 -245 -549 -176 -52 -21
Net Income / (Loss) Continuing Operations		 -30 -241 -245 -549 -176 -52 -21
Total Pre-Tax Income 		-30 -241 -245 -598 -177 -53 -21
Total Operating Income		 -30 -242 -446 -668 -181 -23 -13
Total Gross Profit		 83 4.03 -17 -27 90 194 298
Total Revenue		 196 179 212 235 203 305 428
Operating Revenue		 196 179 212 235 203 305 428
Total Cost of Revenue		 113 175 229 261 113 111 129
Operating Cost of Revenue		 113 175 229 261 113 111 129
Total Operating Expenses		 113 246 430 641 271 218 311
Selling, General & Admin Expense		 29 101 206 216 139 105 151
Marketing Expense		 39 63 113 122 61 67 88
Research & Development Expense		 35 73 105 86 58 46 72
Other Operating Expenses / (Income)		 9.45 9.40 5.66 6.31 1.96 0.00 0.00
Impairment Charge		 - 0.00 0.00 210 10 0.00 0.00
Total Other Income / (Expense), net		 0.71 0.65 201 70 3.90 -29 -8.06
Interest & Investment Income		 0.99 0.51 0.08 - 1.11 -3.03 -2.54
Other Income / (Expense), net		 0.50 2.62 204 70 2.79 -26 -5.52
Income Tax Expense		 0.00 0.00 0.00 -49 -0.93 -0.34 -0.12
Basic Earnings per Share		 ($264,056.00) ($47,036.00) ($2.27) ($53.63) ($7.23) ($1.94) ($0.73)
Weighted Average Basic Shares Outstanding		 124.00 5.13K 108.08M 10.24M 24.31M 26.89M 28.64M
Diluted Earnings per Share		 ($264,056.00) ($47,036.00) ($2.27) ($53.63) ($7.23) ($1.94) ($0.73)
Weighted Average Diluted Shares Outstanding		 124.00 5.13K 108.08M 10.24M 24.31M 26.89M 28.64M
Weighted Average Basic & Diluted Shares Outstanding		 - - 244.96M 798.25M 26.05M 28.07M 29.29M

Quarterly Income Statements for GeneDx

This table shows GeneDx's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -26 -20 -29 -8.31 5.44 -6.53 11 -7.64 -18 -63 -18
Consolidated Net Income / (Loss)		 -26 -20 -29 -8.31 5.44 -6.53 11 -7.64 -18 -63 -18
Net Income / (Loss) Continuing Operations		 -26 -20 -29 -8.31 5.44 -6.53 11 -7.64 -18 -63 -18
Total Pre-Tax Income 		-26 -20 -29 -8.36 5.41 -6.08 11 -7.39 -18 -62 -18
Total Operating Income		 -26 -14 -11 -7.78 8.81 -4.55 8.96 -3.25 -14 -57 -17
Total Gross Profit		 31 37 43 48 66 58 71 85 84 68 78
Total Revenue		 57 62 71 77 96 87 103 117 121 102 114
Operating Revenue		 57 62 71 77 96 87 103 117 121 102 114
Total Cost of Revenue		 27 25 28 29 29 29 32 32 37 34 36
Operating Cost of Revenue		 27 25 28 29 29 29 32 32 37 34 36
Total Operating Expenses		 56 51 54 56 57 63 62 88 99 126 96
Selling, General & Admin Expense		 27 23 26 27 27 50 47 44 47 75 76
Research & Development Expense		 12 12 11 12 12 13 15 20 25 20 20
Impairment Charge		 - - - - - 0.00 0.00 - - 31 0.00
Total Other Income / (Expense), net		 -1.71 -6.66 -19 -0.58 -3.39 -1.53 1.60 -4.14 -4.00 -4.95 -0.80
Interest Expense		 - - - - - 0.00 0.00 - - 6.57 0.00
Interest & Investment Income		 - -0.60 -0.89 -0.84 - -0.64 -0.82 -0.56 -0.52 -0.72 -1.19
Other Income / (Expense), net		 -0.73 -6.06 -18 0.26 -2.69 -0.89 2.42 -3.58 -3.48 2.33 0.38
Income Tax Expense		 -0.41 -0.08 -0.19 -0.05 -0.02 0.45 -0.25 0.25 -0.56 0.90 -0.52
Basic Earnings per Share		 ($1.06) ($0.78) ($1.10) ($0.31) $0.20 ($0.23) $0.38 ($0.27) ($0.61) ($2.16) ($0.60)
Weighted Average Basic Shares Outstanding		 24.31M 26.06M 26.62M 27.10M 26.89M 28.15M 28.58M 28.80M 28.64M 29.34M 29.71M
Diluted Earnings per Share		 ($1.06) ($0.78) ($1.10) ($0.31) $0.20 ($0.23) $0.36 ($0.27) ($0.59) ($2.16) ($0.60)
Weighted Average Diluted Shares Outstanding		 24.31M 26.06M 26.62M 27.10M 26.89M 28.15M 29.75M 28.80M 28.64M 29.34M 29.71M
Weighted Average Basic & Diluted Shares Outstanding		 26.05M 26.14M 26.94M 27.47M 28.07M 28.53M 28.73M 28.90M 29.29M 29.69M 29.82M

Annual Cash Flow Statements for GeneDx

This table details how cash moves in and out of GeneDx's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 114 3.95 283 -263 -38 -14 20
Net Cash From Operating Activities		 -19 -93 -190 -319 -180 -28 33
Net Cash From Continuing Operating Activities		 -19 -93 -192 -319 -180 -28 33
Net Income / (Loss) Continuing Operations		 -30 -241 -245 -549 -176 -52 -21
Consolidated Net Income / (Loss)		 -30 -241 -245 -549 -176 -52 -21
Depreciation Expense		 6.41 12 22 59 34 22 25
Non-Cash Adjustments To Reconcile Net Income		 6.73 123 25 183 3.71 23 42
Changes in Operating Assets and Liabilities, net		 -2.16 14 6.65 -13 -41 -21 -12
Net Cash From Investing Activities		 -15 -32 -21 -141 -44 -30 -62
Net Cash From Continuing Investing Activities		 -15 -32 -21 -141 -44 -30 -62
Purchase of Property, Plant & Equipment		 -15 -32 -21 -14 -5.71 -5.49 -19
Acquisitions		 - 0.00 0.00 -127 -12 0.00 -33
Purchase of Investments		 - - - 0.00 -48 -66 -56
Sale of Property, Plant & Equipment		 - - - 0.00 4.03 0.00 0.00
Sale and/or Maturity of Investments		 - - - 0.00 18 42 46
Net Cash From Financing Activities		 148 129 494 197 186 44 48
Net Cash From Continuing Financing Activities		 148 129 498 197 186 44 48
Repayment of Debt		 -1.71 -0.19 -10 0.00 -2.00 -0.50 -1.21
Issuance of Debt		 0.00 16 0.00 0.00 49 0.00 0.00
Issuance of Common Equity		 0.00 0.00 793 198 143 47 50
Other Financing Activities, net		 31 -4.01 -2.46 -0.34 -3.31 -2.33 -0.43
Cash Interest Paid		 0.31 1.75 2.75 1.93 3.04 6.68 6.41
Cash Income Taxes Paid		 0.00 0.00 0.35 1.24 1.47 1.17 1.28

Quarterly Cash Flow Statements for GeneDx

This table details how cash moves in and out of GeneDx's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 12 -16 -28 1.82 27 14 -26 22 9.03 -11 -34
Net Cash From Operating Activities		 -30 -16 -4.51 -4.40 -3.18 10 10 16 -3.09 -32 -29
Net Cash From Continuing Operating Activities		 -30 -16 -4.51 -4.40 -3.45 10 10 16 -3.09 -32 -29
Net Income / (Loss) Continuing Operations		 -26 -20 -29 -8.31 5.44 -6.53 11 -7.64 -18 -63 -18
Consolidated Net Income / (Loss)		 -26 -20 -29 -8.31 5.44 -6.53 11 -7.64 -18 -63 -18
Depreciation Expense		 6.09 5.25 5.22 5.93 5.56 5.68 6.19 6.47 6.88 6.81 6.71
Non-Cash Adjustments To Reconcile Net Income		 -2.74 5.46 22 2.89 -7.99 6.48 9.37 19 7.10 45 4.08
Changes in Operating Assets and Liabilities, net		 -7.44 -6.88 -2.85 -4.90 -6.45 4.56 -16 -1.63 0.60 -21 -22
Net Cash From Investing Activities		 -4.86 0.84 -23 -7.76 -0.52 -9.41 -36 -4.69 -11 -17 -5.63
Net Cash From Continuing Investing Activities		 -4.86 0.84 -23 -7.76 -0.52 -9.41 -36 -4.69 -11 -17 -5.63
Purchase of Property, Plant & Equipment		 -2.38 -0.44 -1.35 -0.65 -3.05 -6.13 -2.37 -6.17 -4.35 -6.45 -10
Purchase of Investments		 -3.74 -5.17 -24 -23 -14 -17 -14 -5.77 -19 -20 -8.89
Sale and/or Maturity of Investments		 1.10 6.45 2.87 16 16 14 13 7.25 12 9.38 13
Net Cash From Financing Activities		 47 -0.44 -0.39 14 31 14 0.35 11 23 39 1.01
Net Cash From Continuing Financing Activities		 47 -0.44 -0.39 14 31 14 0.35 11 23 39 1.01
Issuance of Common Equity		 - 0.00 - 15 32 14 1.13 12 23 97 -95
Other Financing Activities, net		 -1.45 -0.44 -0.39 -0.42 -1.08 0.12 -0.49 -0.73 0.66 -0.44 -0.49
Cash Interest Paid		 1.93 2.02 2.01 2.04 0.61 1.60 1.61 1.63 1.58 1.75 2.07
Cash Income Taxes Paid		 0.29 0.30 0.26 0.35 0.26 0.21 0.71 0.12 0.24 0.75 1.47

Annual Balance Sheets for GeneDx

This table presents GeneDx's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 252 554 491 419 419 524
Total Current Assets		 174 484 213 182 198 268
Cash & Equivalents		 108 401 124 100 85 105
Short-Term Investments		 - - 0.00 30 56 66
Accounts Receivable		 32 27 43 33 38 74
Inventories, net		 25 33 14 8.78 11 14
Prepaid Expenses		 4.56 19 32 11 8.50 8.69
Plant, Property, & Equipment, net		 63 63 52 32 33 46
Total Noncurrent Assets		 14 7.83 227 204 189 210
Goodwill		 - - - - 0.00 14
Intangible Assets		 - 0.00 187 173 159 168
Other Noncurrent Operating Assets		 14 7.83 40 31 30 28
Total Liabilities & Shareholders' Equity		 252 554 491 419 419 524
Total Liabilities		 247 166 237 191 174 216
Total Current Liabilities		 73 101 144 59 55 109
Accounts Payable		 28 47 85 37 31 58
Other Current Liabilities		 30 34 59 21 24 51
Total Noncurrent Liabilities		 174 65 93 132 119 107
Long-Term Debt		 19 11 6.25 53 52 48
Capital Lease Obligations		 21 0.00 60 63 61 56
Noncurrent Deferred & Payable Income Tax Liabilities		 - 0.00 2.66 1.56 0.97 0.76
Other Noncurrent Operating Liabilities		 2.07 54 24 15 5.52 1.64
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -330 388 254 228 245 308
Total Preferred & Common Equity		 -330 388 254 228 245 308
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -330 388 254 228 245 308
Common Stock		 0.00 964 1,378 1,528 1,597 1,681
Retained Earnings		 -330 -575 -1,124 -1,300 -1,352 -1,373
Accumulated Other Comprehensive Income / (Loss)		 - - 0.00 0.43 0.83 0.94

Quarterly Balance Sheets for GeneDx

This table presents GeneDx's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 545 476 417 395 389 409 446 464 494 506 481
Total Current Assets		 272 213 172 163 162 186 226 205 238 271 246
Cash & Equivalents		 202 157 87 84 56 58 100 74 96 94 60
Short-Term Investments		 - - 27 29 51 59 59 60 59 77 72
Accounts Receivable		 34 34 32 29 26 38 46 48 61 77 84
Inventories, net		 12 12 9.35 12 10 11 13 12 11 12 18
Prepaid Expenses		 12 11 16 9.97 19 20 8.01 10 11 11 12
Plant, Property, & Equipment, net		 50 43 36 31 31 31 36 40 42 50 54
Total Noncurrent Assets		 223 220 210 200 196 191 184 219 214 186 181
Goodwill		 - - - - - - - 13 13 1.64 1.64
Intangible Assets		 183 180 176 169 166 162 155 177 173 145 141
Other Noncurrent Operating Assets		 40 40 34 31 30 29 29 29 29 39 38
Total Liabilities & Shareholders' Equity		 545 476 417 395 389 409 446 464 494 506 481
Total Liabilities		 217 180 163 187 195 204 189 187 202 252 237
Total Current Liabilities		 119 84 68 51 68 77 70 71 88 88 75
Accounts Payable		 74 55 39 32 52 56 42 49 50 47 42
Other Current Liabilities		 45 30 29 18 16 21 28 22 37 41 33
Total Noncurrent Liabilities		 98 96 95 137 127 127 119 115 114 165 163
Long-Term Debt		 6.25 6.25 6.05 52 52 52 52 52 52 97 97
Capital Lease Obligations		 64 64 64 62 61 60 60 60 57 66 65
Noncurrent Deferred & Payable Income Tax Liabilities		 2.51 2.25 2.06 1.42 1.17 1.05 1.15 0.75 1.03 1.40 0.87
Other Noncurrent Operating Liabilities		 25 24 23 21 13 14 6.62 3.28 4.26 0.07 0.07
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 328 296 254 207 194 205 257 277 292 254 244
Total Preferred & Common Equity		 328 296 254 207 194 205 257 277 292 254 244
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 328 296 254 207 194 205 257 277 292 254 244
Common Stock		 1,514 1,528 1,529 1,527 1,543 1,561 1,616 1,625 1,647 1,690 1,698
Retained Earnings		 -1,185 -1,232 -1,274 -1,320 -1,350 -1,358 -1,359 -1,348 -1,356 -1,437 -1,455
Accumulated Other Comprehensive Income / (Loss)		 - - - 0.29 0.46 0.92 0.91 0.81 1.00 0.68 0.34

Annual Metrics And Ratios for GeneDx

This table displays calculated financial ratios and metrics derived from GeneDx's official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% -8.59% 18.33% 10.60% -13.69% 50.79% 39.97%
EBITDA Growth		 0.00% -868.59% 3.02% -143.73% 73.01% 80.97% 123.97%
EBIT Growth		 0.00% -700.33% -1.36% -146.20% 70.04% 72.29% 62.50%
NOPAT Growth		 0.00% -695.69% -84.36% -49.65% 72.95% 87.15% 43.67%
Net Income Growth		 0.00% -712.48% -1.68% -123.72% 67.98% 70.25% 59.80%
EPS Growth		 0.00% 82.19% 100.00% -123.72% 86.52% 73.17% 62.37%
Operating Cash Flow Growth		 0.00% -397.27% -104.49% -67.59% 43.56% 84.18% 216.78%
Free Cash Flow Firm Growth		 0.00% 0.00% -240.96% -79.05% 78.36% 86.34% -69.90%
Invested Capital Growth		 0.00% 0.00% 97.58% 13,472.10% 8.91% 1.59% 11.17%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 1.54% -1.90% 14.30% 6.30%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% -81.56% 63.68% 52.69% -77.25%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% -82.20% 61.23% 38.70% -456.01%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% -45.60% 62.36% 59.74% -210.57%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% -95.78% 61.69% 37.38% -1,109.17%
EPS Q/Q Growth		 0.00% 0.00% 0.00% -95.78% 59.36% 37.01% -1,142.86%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -21.46% -4.13% 16.19% 48.35% 0.28%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -39.87% 36.43% 10.24%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% -55.74% 1.71% 8.21% -1.95%
Profitability Metrics		 - - - - - - -
Gross Margin		 42.20% 2.25% -7.82% -11.40% 44.43% 63.64% 69.74%
EBITDA Margin		 -11.98% -126.94% -104.04% -229.26% -71.70% -9.05% 1.55%
Operating Margin		 -15.50% -134.95% -210.25% -284.48% -89.15% -7.60% -3.06%
EBIT Margin		 -15.25% -133.49% -114.34% -254.53% -88.35% -16.24% -4.35%
Profit (Net Income) Margin		 -15.14% -134.58% -115.64% -233.91% -86.77% -17.12% -4.92%
Tax Burden Percent		 100.00% 100.00% 100.00% 91.80% 99.48% 99.35% 99.45%
Interest Burden Percent		 99.31% 100.82% 101.14% 100.11% 98.72% 106.11% 113.65%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% -480.40% -61.74% -7.55% -4.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% -443.90% 74.98% 160.55% 20.88%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 309.33% -11.24% -14.55% -3.60%
Return on Equity (ROE)		 0.00% -5,500.00% -125.04% -171.07% -72.97% -22.10% -7.60%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -339.15% -70.26% -9.13% -14.58%
Operating Return on Assets (OROA)		 0.00% -95.12% -60.23% -114.32% -39.35% -11.84% -3.94%
Return on Assets (ROA)		 0.00% -95.91% -60.91% -105.06% -38.64% -12.48% -4.46%
Return on Common Equity (ROCE)		 0.00% 413,692.00% -18.49% -171.07% -72.97% -22.10% -7.60%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 73.12% -63.23% -216.39% -77.09% -21.32% 0.00%
Net Operating Profit after Tax (NOPAT)		 -21 -169 -312 -467 -126 -16 -9.15
NOPAT Margin		 -10.85% -94.46% -147.18% -199.13% -62.41% -5.32% -2.14%
Net Nonoperating Expense Percent (NNEP)		 0.00% -221.79% 29.45% -36.50% -136.72% -168.10% -24.88%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -36.79% -4.54% -2.22%
Cost of Revenue to Revenue		 57.80% 97.75% 107.82% 111.40% 55.57% 36.36% 30.26%
SG&A Expenses to Revenue		 15.03% 56.18% 97.07% 92.11% 66.03% 33.10% 35.28%
R&D to Revenue		 17.80% 40.54% 49.56% 36.73% 28.76% 14.97% 16.85%
Operating Expenses to Revenue		 57.70% 137.19% 202.43% 273.08% 133.59% 71.24% 72.80%
Earnings before Interest and Taxes (EBIT)		 -30 -239 -243 -597 -179 -50 -19
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -24 -228 -221 -538 -145 -28 6.63
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 2.77 0.40 0.31 8.61 12.20
Price to Tangible Book Value (P/TBV)		 0.00 0.00 2.77 1.52 1.29 24.37 29.79
Price to Revenue (P/Rev)		 1.96 3.41 5.07 0.43 0.35 6.91 8.79
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.23 0.27 9.60 15.31
Enterprise Value to Revenue (EV/Rev)		 0.00 4.91 3.24 0.19 0.28 6.82 8.64
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 557.24
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 110.95
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 9.86 0.03 0.26 0.51 0.46 0.34
Long-Term Debt to Equity		 0.00 9.06 0.03 0.26 0.51 0.46 0.34
Financial Leverage		 0.00 -14.79 -1.16 -0.70 -0.15 -0.09 -0.17
Leverage Ratio		 0.00 57.35 2.05 1.63 1.89 1.77 1.70
Compound Leverage Factor		 0.00 57.82 2.08 1.63 1.86 1.88 1.94
Debt to Total Capital		 0.00% 90.79% 2.76% 20.71% 33.65% 31.51% 25.27%
Short-Term Debt to Total Capital		 0.00% 7.36% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 83.43% 2.76% 20.71% 33.65% 31.51% 25.27%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 701.97% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -692.76% 97.24% 79.29% 66.35% 68.49% 74.73%
Debt to EBITDA		 0.00 -0.19 -0.05 -0.12 -0.80 -4.08 15.73
Net Debt to EBITDA		 0.00 0.29 1.76 0.11 0.10 1.03 -10.12
Long-Term Debt to EBITDA		 0.00 -0.17 -0.05 -0.12 -0.80 -4.08 15.73
Debt to NOPAT		 0.00 -0.26 -0.04 -0.14 -0.91 -6.94 -11.39
Net Debt to NOPAT		 0.00 0.38 1.25 0.12 0.11 1.74 7.33
Long-Term Debt to NOPAT		 0.00 -0.23 -0.04 -0.14 -0.91 -6.94 -11.39
Altman Z-Score		 0.00 -2.30 2.20 -6.32 -4.70 3.51 7.86
Noncontrolling Interest Sharing Ratio		 0.00% 7,621.67% 85.21% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 0.00 2.37 4.77 1.47 3.10 3.61 2.46
Quick Ratio		 0.00 1.91 4.22 1.16 2.77 3.26 2.26
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -109 -371 -665 -144 -20 -33
Operating Cash Flow to CapEx		 -121.17% -291.26% -916.16% -2,228.42% -10,742.22% -518.96% 175.00%
Free Cash Flow to Firm to Interest Expense		 0.00 -44.02 -130.98 -998.28 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -23.92 -37.64 -67.17 -479.21 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -43.66 -50.57 -74.50 -500.72 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.71 0.53 0.45 0.45 0.73 0.91
Accounts Receivable Turnover		 0.00 5.55 7.21 6.71 5.32 8.67 7.63
Inventory Turnover		 0.00 7.02 7.83 11.10 10.03 11.43 10.52
Fixed Asset Turnover		 0.00 2.84 3.37 4.11 4.82 9.35 10.88
Accounts Payable Turnover		 0.00 6.22 6.06 3.96 1.84 3.29 2.92
Days Sales Outstanding (DSO)		 0.00 65.81 50.65 54.36 68.61 42.09 47.81
Days Inventory Outstanding (DIO)		 0.00 51.98 46.60 32.89 36.39 31.93 34.71
Days Payable Outstanding (DPO)		 0.00 58.64 60.21 92.28 198.35 110.93 125.03
Cash Conversion Cycle (CCC)		 0.00 59.15 37.05 -5.03 -93.35 -36.91 -42.52
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 0.00 -60 -1.47 196 213 217 241
Invested Capital Turnover		 0.00 -5.93 -6.85 2.41 0.99 1.42 1.87
Increase / (Decrease) in Invested Capital		 0.00 -60 59 198 17 3.40 24
Enterprise Value (EV)		 0.00 881 686 44 57 2,083 3,692
Market Capitalization		 385 611 1,076 102 71 2,111 3,759
Book Value per Share		 $0.00 ($5.96) $1.61 $0.66 $8.81 $8.93 $10.66
Tangible Book Value per Share		 $0.00 ($5.96) $1.61 $0.17 $2.14 $3.15 $4.37
Total Capital		 0.00 48 399 320 344 358 412
Total Debt		 0.00 43 11 66 116 113 104
Total Long-Term Debt		 0.00 40 11 66 116 113 104
Net Debt		 0.00 -65 -390 -58 -15 -28 -67
Capital Expenditures (CapEx)		 15 32 21 14 1.68 5.49 19
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -3.96 -18 -56 -6.63 1.97 -12
Debt-free Net Working Capital (DFNWC)		 0.00 104 382 68 124 143 159
Net Working Capital (NWC)		 0.00 101 382 68 124 143 159
Net Nonoperating Expense (NNE)		 8.41 72 -67 82 49 36 12
Net Nonoperating Obligations (NNO)		 0.00 -65 -390 -58 -15 -28 -67
Total Depreciation and Amortization (D&A)		 6.41 12 22 59 34 22 25
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -2.21% -8.63% -23.69% -3.27% 0.64% -2.78%
Debt-free Net Working Capital to Revenue		 0.00% 58.09% 180.15% 29.11% 60.98% 46.87% 37.28%
Net Working Capital to Revenue		 0.00% 56.14% 180.15% 29.11% 60.98% 46.87% 37.28%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 ($53.79) ($7.23) ($1.94) ($0.73)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 10.24M 24.31M 26.89M 28.64M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($53.79) ($7.23) ($1.94) ($0.73)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 10.24M 24.31M 26.89M 28.64M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 24.19M 26.05M 28.07M 29.29M
Normalized Net Operating Profit after Tax (NOPAT)		 -21 -169 -312 -320 -119 -16 -9.15
Normalized NOPAT Margin		 -10.85% -94.46% -147.18% -136.46% -58.81% -5.32% -2.14%
Pre Tax Income Margin		 -15.14% -134.58% -115.64% -254.81% -87.23% -17.23% -4.94%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 -38.20 -96.76 -85.59 -896.95 0.00 0.00 0.00
NOPAT to Interest Expense		 -27.19 -68.47 -110.16 -701.74 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -57.94 -109.68 -92.92 -918.45 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -46.93 -81.39 -117.49 -723.24 0.00 0.00 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% -21.09% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% -21.09% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for GeneDx

This table displays calculated financial ratios and metrics derived from GeneDx's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - - 29,288,739.00 29,688,027.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 29,288,739.00 29,688,027.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - -2.16 -0.60
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -6.41% 44.70% 44.77% 44.22% 66.57% 39.56% 45.63% 51.86% 26.50% 17.38% 11.44%
EBITDA Growth		 92.62% 72.41% 38.26% 95.44% 157.54% 101.63% 175.57% 77.82% -192.79% -20,577.97% -158.96%
EBIT Growth		 91.46% 67.72% 40.68% 82.73% 123.17% 72.41% 139.97% 9.18% -389.76% -913.18% -250.03%
NOPAT Growth		 92.11% 77.37% 79.51% 81.89% 149.28% 66.68% 223.81% 58.21% -212.66% -1,162.82% -233.26%
Net Income Growth		 91.65% 66.82% 37.56% 80.34% 121.10% 67.74% 137.05% 8.14% -424.86% -869.77% -264.12%
EPS Growth		 96.49% 74.34% 40.22% 81.10% 118.87% 70.51% 132.73% 12.90% -395.00% -839.13% -266.67%
Operating Cash Flow Growth		 53.82% 70.46% 91.58% 89.34% 89.34% 162.04% 331.30% 458.75% 2.92% -418.29% -378.13%
Free Cash Flow Firm Growth		 91.67% 76.63% -98.95% -98.02% 115.38% 86.57% -2,436.08% -1,290.00% -727.84% -1,600.55% 28.85%
Invested Capital Growth		 8.91% 13.04% -4.45% -4.51% 1.59% 0.64% 26.85% 22.68% 11.17% 17.41% 7.68%
Revenue Q/Q Growth		 7.72% 8.72% 12.96% 9.02% 24.41% -8.91% 17.88% 13.68% 3.64% -15.48% 11.92%
EBITDA Q/Q Growth		 41.78% 24.26% -60.62% 93.17% 835.35% -97.98% 7,345.34% -102.00% -2,976.42% -346.28% 78.57%
EBIT Q/Q Growth		 39.38% 21.75% -44.34% 73.60% 181.32% -189.04% 309.11% -159.98% -159.45% -211.33% 69.04%
NOPAT Q/Q Growth		 40.32% 46.73% 22.55% 26.46% 262.41% -136.02% 387.81% -124.82% -337.87% -303.73% 69.63%
Net Income Q/Q Growth		 39.05% 21.47% -44.14% 71.51% 165.42% -220.06% 265.55% -170.64% -131.38% -258.41% 71.98%
EPS Q/Q Growth		 35.37% 26.42% -41.03% 71.82% 164.52% -215.00% 256.52% -175.00% -118.52% -266.10% 72.22%
Operating Cash Flow Q/Q Growth		 27.58% 45.03% 72.55% 2.44% 27.58% 419.89% 2.34% 51.31% -119.60% -948.80% 10.57%
Free Cash Flow Firm Q/Q Growth		 -117.45% 5.04% 105.67% 110.31% 35.74% -182.90% -887.12% -7.13% 28.38% -124.54% 58.70%
Invested Capital Q/Q Growth		 1.71% -2.28% -4.07% 0.15% 8.21% -3.20% 20.92% -3.14% -1.95% 2.23% 10.90%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 53.56% 59.93% 60.91% 62.22% 69.22% 67.13% 69.04% 72.40% 69.65% 66.71% 68.37%
EBITDA Margin		 -35.32% -23.19% -32.97% -2.06% 12.20% 0.27% 17.11% -0.30% -8.95% -47.26% -9.05%
Operating Margin		 -44.66% -21.88% -15.00% -10.12% 9.21% -5.22% 8.73% -2.78% -11.77% -56.20% -15.25%
EBIT Margin		 -45.94% -31.60% -40.37% -9.78% 6.39% -6.25% 11.08% -5.85% -14.64% -53.92% -14.92%
Profit (Net Income) Margin		 -44.89% -32.42% -41.37% -10.81% 5.69% -7.49% 10.53% -6.54% -14.60% -61.92% -15.50%
Tax Burden Percent		 98.43% 99.60% 99.35% 99.44% 100.44% 107.35% 102.33% 103.34% 96.91% 101.44% 97.16%
Interest Burden Percent		 99.27% 103.03% 103.14% 111.22% 88.58% 111.76% 92.82% 108.23% 102.94% 113.21% 106.94%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% -0.44% 0.00% -2.33% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -30.93% -17.29% -12.49% -9.23% 13.13% -5.77% 14.25% -3.51% -15.38% -76.31% -18.40%
ROIC Less NNEP Spread (ROIC-NNEP)		 -9.25% -2.30% 41.55% 2.61% 29.02% 8.76% -4.87% 17.75% 0.77% 7.53% -205.92%
Return on Net Nonoperating Assets (RNNOA)		 1.39% 0.61% -6.83% -0.28% -2.63% -0.87% 0.18% -1.80% -0.13% -0.81% -2.33%
Return on Equity (ROE)		 -29.54% -16.67% -19.32% -9.50% 10.50% -6.64% 14.43% -5.31% -15.51% -77.12% -20.73%
Cash Return on Invested Capital (CROIC)		 -70.26% -59.91% -27.19% -15.06% -9.13% -5.35% -21.48% -16.66% -14.58% -36.25% -31.93%
Operating Return on Assets (OROA)		 -20.46% -14.92% -22.73% -6.33% 4.66% -4.90% 9.41% -5.21% -13.27% -50.11% -14.34%
Return on Assets (ROA)		 -19.99% -15.31% -23.29% -7.00% 4.14% -5.88% 8.94% -5.83% -13.24% -57.54% -14.90%
Return on Common Equity (ROCE)		 -29.54% -16.67% -19.32% -9.50% 10.50% -6.64% 14.43% -5.31% -15.51% -77.12% -20.73%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -65.16% -60.54% -40.83% 0.00% -14.99% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -18 -9.56 -7.41 -5.45 8.85 -3.19 9.17 -2.28 -9.96 -40 -12
NOPAT Margin		 -31.26% -15.32% -10.50% -7.08% 9.25% -3.66% 8.93% -1.95% -8.24% -39.34% -10.68%
Net Nonoperating Expense Percent (NNEP)		 -21.67% -14.99% -54.04% -11.84% -15.89% -14.52% 19.12% -21.27% -16.14% -83.84% 187.52%
Return On Investment Capital (ROIC_SIMPLE)		 -5.22% - - - 2.47% -0.86% 2.36% -0.57% -2.42% -9.64% -3.01%
Cost of Revenue to Revenue		 46.44% 40.07% 39.09% 37.78% 30.78% 32.87% 30.96% 27.60% 30.35% 33.29% 31.63%
SG&A Expenses to Revenue		 46.37% 35.96% 35.70% 34.01% 28.60% 36.89% 26.70% 38.07% 38.71% 72.95% 66.44%
R&D to Revenue		 21.33% 18.53% 15.46% 15.17% 12.12% 14.44% 14.68% 16.99% 20.28% 19.37% 17.18%
Operating Expenses to Revenue		 98.22% 81.82% 75.92% 72.34% 60.02% 72.35% 60.32% 75.19% 81.41% 122.91% 83.62%
Earnings before Interest and Taxes (EBIT)		 -26 -20 -28 -7.52 6.11 -5.44 11 -6.83 -18 -55 -17
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -20 -14 -23 -1.59 12 0.24 18 -0.35 -11 -48 -10
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.31 1.14 3.52 5.59 8.61 9.66 9.50 10.59 12.20 7.40 8.35
Price to Tangible Book Value (P/TBV)		 1.29 6.20 24.04 26.96 24.37 24.30 30.10 28.96 29.79 17.49 20.13
Price to Revenue (P/Rev)		 0.35 1.07 2.80 4.28 6.91 7.53 7.27 7.70 8.79 4.25 4.49
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 1,873.33 1,485.82 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.05% 0.07% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.27 1.14 3.44 5.68 9.60 11.61 10.28 12.40 15.31 7.60 7.56
Enterprise Value to Revenue (EV/Rev)		 0.28 1.07 2.83 4.26 6.82 7.39 7.21 7.58 8.64 4.23 4.55
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 93.61 104.67 557.24 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 575.79 583.58 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 524.75 368.24 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 200.45 91.86 110.95 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.51 0.55 0.58 0.55 0.46 0.43 0.40 0.37 0.34 0.64 0.66
Long-Term Debt to Equity		 0.51 0.55 0.58 0.55 0.46 0.43 0.40 0.37 0.34 0.64 0.66
Financial Leverage		 -0.15 -0.27 -0.16 -0.11 -0.09 -0.10 -0.04 -0.10 -0.17 -0.11 0.01
Leverage Ratio		 1.89 1.75 1.77 1.80 1.77 1.81 1.81 1.82 1.70 1.86 1.81
Compound Leverage Factor		 1.87 1.81 1.82 2.00 1.57 2.02 1.68 1.97 1.75 2.11 1.94
Debt to Total Capital		 33.65% 35.55% 36.79% 35.47% 31.51% 30.26% 28.65% 27.12% 25.27% 39.09% 39.83%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 33.65% 35.55% 36.79% 35.47% 31.51% 30.26% 28.65% 27.12% 25.27% 39.09% 39.83%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 66.35% 64.45% 63.21% 64.53% 68.49% 69.74% 71.35% 72.88% 74.73% 60.91% 60.17%
Debt to EBITDA		 -0.80 -1.08 -1.23 -1.92 -4.08 -8.64 3.99 3.73 15.73 -3.89 -2.31
Net Debt to EBITDA		 0.10 -0.01 -0.07 0.07 1.03 3.67 -0.83 -1.59 -10.12 0.18 -0.42
Long-Term Debt to EBITDA		 -0.80 -1.08 -1.23 -1.92 -4.08 -8.64 3.99 3.73 15.73 -3.89 -2.31
Debt to NOPAT		 -0.91 -1.22 -1.74 -2.78 -6.94 -11.32 22.37 13.13 -11.39 -3.53 -2.50
Net Debt to NOPAT		 0.11 -0.02 -0.09 0.10 1.74 4.81 -4.67 -5.60 7.33 0.17 -0.45
Long-Term Debt to NOPAT		 -0.91 -1.22 -1.74 -2.78 -6.94 -11.32 22.37 13.13 -11.39 -3.53 -2.50
Altman Z-Score		 -3.49 -3.19 -2.08 -0.38 3.95 4.75 5.60 6.50 7.86 1.45 2.18
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.10 3.22 2.38 2.41 3.61 3.25 2.87 2.71 2.46 3.09 3.30
Quick Ratio		 2.77 2.80 1.95 2.00 3.26 2.95 2.56 2.47 2.26 2.83 2.90
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -35 -34 1.91 4.01 5.45 -4.51 -45 -48 -34 -77 -32
Operating Cash Flow to CapEx		 -1,339.52% -3,704.97% -333.21% -680.34% -104.36% 166.13% 439.85% 255.46% -71.08% -502.22% -286.54%
Free Cash Flow to Firm to Interest Expense		 0.00 -56.33 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -11.69 0.00
Operating Cash Flow to Interest Expense		 0.00 -27.49 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -4.94 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -28.23 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -5.92 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.45 0.47 0.56 0.65 0.73 0.79 0.85 0.89 0.91 0.93 0.96
Accounts Receivable Turnover		 5.32 7.10 8.11 7.54 8.67 8.81 9.76 8.09 7.63 7.20 6.90
Inventory Turnover		 10.03 9.16 9.82 10.76 11.43 9.45 10.69 11.44 10.52 10.82 9.36
Fixed Asset Turnover		 4.82 5.49 6.53 7.95 9.35 9.76 10.14 10.89 10.88 10.23 9.62
Accounts Payable Turnover		 1.84 2.06 2.01 2.27 3.29 3.09 2.35 2.29 2.92 3.05 3.05
Days Sales Outstanding (DSO)		 68.61 51.39 45.01 48.41 42.09 41.41 37.38 45.11 47.81 50.67 52.87
Days Inventory Outstanding (DIO)		 36.39 39.85 37.18 33.91 31.93 38.63 34.16 31.90 34.71 33.72 39.01
Days Payable Outstanding (DPO)		 198.35 177.42 181.56 160.60 110.93 118.19 155.32 159.58 125.03 119.74 119.75
Cash Conversion Cycle (CCC)		 -93.35 -86.17 -99.37 -78.28 -36.91 -38.15 -83.78 -82.57 -42.52 -35.35 -27.88
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 213 209 200 200 217 210 254 246 241 247 273
Invested Capital Turnover		 0.99 1.13 1.19 1.30 1.42 1.58 1.60 1.80 1.87 1.94 1.72
Increase / (Decrease) in Invested Capital		 17 24 -9.31 -9.46 3.40 1.33 54 45 24 37 19
Enterprise Value (EV)		 57 238 689 1,139 2,083 2,438 2,611 3,049 3,692 1,873 2,067
Market Capitalization		 71 236 683 1,143 2,111 2,486 2,634 3,095 3,759 1,881 2,038
Book Value per Share		 $8.81 $7.95 $7.42 $7.59 $8.93 $9.17 $9.71 $10.17 $10.66 $8.68 $8.23
Tangible Book Value per Share		 $2.14 $1.46 $1.09 $1.57 $3.15 $3.65 $3.07 $3.72 $4.37 $3.67 $3.41
Total Capital		 344 322 307 317 358 369 388 401 412 417 406
Total Debt		 116 114 113 112 113 112 111 109 104 163 162
Total Long-Term Debt		 116 114 113 112 113 112 111 109 104 163 162
Net Debt		 -15 1.41 6.10 -4.06 -28 -47 -23 -46 -67 -7.62 29
Capital Expenditures (CapEx)		 2.23 0.44 1.35 0.65 3.05 6.13 2.37 6.17 4.35 6.45 10
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -6.63 -0.22 -13 -7.79 1.97 -2.89 -1.13 -5.12 -12 12 39
Debt-free Net Working Capital (DFNWC)		 124 113 94 109 143 156 133 150 159 183 172
Net Working Capital (NWC)		 124 113 94 109 143 156 133 150 159 183 172
Net Nonoperating Expense (NNE)		 7.82 11 22 2.87 3.41 3.34 -1.64 5.36 7.70 23 5.52
Net Nonoperating Obligations (NNO)		 -15 1.41 6.10 -4.06 -28 -47 -23 -46 -67 -7.62 29
Total Depreciation and Amortization (D&A)		 6.09 5.25 5.22 5.93 5.56 5.68 6.19 6.47 6.88 6.81 6.71
Debt-free, Cash-free Net Working Capital to Revenue		 -3.27% -0.10% -5.32% -2.92% 0.64% -0.87% -0.31% -1.27% -2.78% 2.78% 8.62%
Debt-free Net Working Capital to Revenue		 60.98% 50.80% 38.54% 40.66% 46.87% 47.34% 36.83% 37.29% 37.28% 41.34% 37.79%
Net Working Capital to Revenue		 60.98% 50.80% 38.54% 40.66% 46.87% 47.34% 36.83% 37.29% 37.28% 41.34% 37.79%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.06) ($0.78) ($1.10) ($0.31) $0.20 ($0.23) $0.38 ($0.27) ($0.61) ($2.16) ($0.60)
Adjusted Weighted Average Basic Shares Outstanding		 24.31M 26.06M 26.62M 27.10M 26.89M 28.15M 28.58M 28.80M 28.64M 29.34M 29.71M
Adjusted Diluted Earnings per Share		 ($1.06) ($0.78) ($1.10) ($0.31) $0.20 ($0.23) $0.36 ($0.27) ($0.59) ($2.16) ($0.60)
Adjusted Weighted Average Diluted Shares Outstanding		 24.31M 26.06M 26.62M 27.10M 26.89M 28.15M 29.75M 28.80M 28.64M 29.34M 29.71M
Adjusted Basic & Diluted Earnings per Share		 ($1.06) $0.00 $0.00 $0.00 $0.20 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 26.05M 26.14M 26.94M 27.47M 28.07M 28.53M 28.73M 28.90M 29.29M 29.69M 29.82M
Normalized Net Operating Profit after Tax (NOPAT)		 -18 -9.56 -7.41 -5.45 6.16 -3.19 6.27 -2.28 -9.96 -18 -12
Normalized NOPAT Margin		 -31.26% -15.32% -10.50% -7.08% 6.45% -3.66% 6.11% -1.95% -8.24% -17.92% -10.68%
Pre Tax Income Margin		 -45.60% -32.55% -41.64% -10.87% 5.66% -6.98% 10.29% -6.33% -15.07% -61.04% -15.95%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 -33.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -8.40 0.00
NOPAT to Interest Expense		 0.00 -16.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -6.13 0.00
EBIT Less CapEx to Interest Expense		 0.00 -33.78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -9.38 0.00
NOPAT Less CapEx to Interest Expense		 0.00 -16.76 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -7.11 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

GeneDx’s Q2 2026 results show continued revenue growth, but profitability and cash generation deteriorated sharply. Revenue increased to $114.4 million from $102.7 million in Q2 2025, an 11.4% year-over-year gain. However, the company reported a $17.7 million net loss, compared with $10.8 million of net income in the prior-year quarter.

Revenue has expanded substantially from $48.7 million in Q2 2023 and $70.5 million in Q2 2024. Gross profit also rose to $78.2 million in Q2 2026 from $70.9 million in Q2 2025. Still, gross margin slipped slightly to approximately 68.4% from 69.0%, indicating that cost growth modestly outpaced revenue growth.

  • Strong multi-year revenue growth: Quarterly revenue rose from $48.7 million in Q2 2023 to $114.4 million in Q2 2026, reflecting significant expansion in GeneDx’s business.
  • Improved gross profit scale: Gross profit increased to $78.2 million in Q2 2026 from $42.0 million in Q2 2024 and $18.8 million in Q2 2023.
  • Reduced loss compared with Q1 2026: The Q2 net loss of $17.7 million was substantially narrower than the $63.3 million loss reported in Q1 2026, when the company recorded a $31.3 million impairment charge.
  • Solid liquidity cushion: Cash and short-term investments totaled approximately $132.5 million at June 30, 2026. Current assets of $246.4 million exceeded current liabilities of $74.6 million by a wide margin.
  • Debt levels have been relatively stable recently: Long-term debt was $96.8 million at June 30, 2026, broadly unchanged from Q1 2026 and Q2 2025, although capital lease obligations add another $64.9 million.
  • Investment in operating capacity continues: Net property, plant and equipment increased to $54.3 million from $40.1 million in Q2 2024, suggesting ongoing investment in laboratory and operational infrastructure.
  • Gross margin remains high but is no longer expanding: The approximately 68% Q2 2026 gross margin remains attractive, but it was slightly below the prior-year level and well below the improvement seen from 2023.
  • Accounts receivable growth warrants monitoring: Receivables reached $83.6 million, up from $48.0 million in Q2 2025. This may reflect business growth, but it also contributed to working-capital pressure and should be monitored for collection trends.
  • Operating expenses grew faster than revenue: Total operating expenses increased to $95.7 million in Q2 2026 from $61.9 million in Q2 2025. Selling, general and administrative expense rose to $76.0 million from $46.9 million, while research and development expense increased to $19.7 million from $15.1 million.
  • Profitability has become inconsistent: GeneDx moved from a $10.8 million profit in Q2 2025 to a $17.7 million loss in Q2 2026. Operating income also swung from a $9.0 million profit to a $17.5 million loss.
  • Operating cash flow remains negative: Cash used in operating activities was $29.0 million in Q2 2026, following a $32.4 million outflow in Q1. This compares with positive operating cash flow of $10.4 million in Q2 2025 and $15.8 million in Q3 2025.
  • Working capital consumed significant cash: Changes in operating assets and liabilities reduced Q2 2026 operating cash flow by $22.0 million, compared with a $15.0 million use in Q2 2025.
  • Cash balances are declining from the start of 2026: Cash and equivalents fell from $93.9 million at March 31, 2026, to $60.3 million at June 30. Cash and short-term investments declined by roughly $35.5 million during the quarter.
  • Repeated equity financing creates dilution risk: Common-stock issuance was significant in Q1 2026, Q4 2025 and earlier periods. Basic weighted-average shares increased to 29.7 million in Q2 2026 from 28.6 million in Q2 2025, diluting existing shareholders.
  • Balance-sheet losses remain substantial: Retained earnings were negative $1.45 billion at June 30, 2026. In addition, intangible assets totaled $141.4 million, and the $31.3 million impairment charge in Q1 highlights the risk of future noncash write-downs.

Overall, GeneDx’s central investment case is its strong top-line growth and sizable gross-profit base. The main risks are that elevated selling and administrative costs, working-capital needs and recurring losses could continue consuming cash. Investors should focus on whether revenue growth can translate into positive operating cash flow without relying on additional equity financing.

09/11/26 11:34 PM ETAI Generated. May Contain Errors.

GeneDx Financials - Frequently Asked Questions

According to the most recent income statement we have on file, GeneDx's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

GeneDx's net income appears to be on a downward trend, with a most recent value of -$21.02 million in 2025, falling from -$29.70 million in 2019. The previous period was -$52.29 million in 2024. Check out GeneDx's forecast to explore projected trends and price targets.

GeneDx's total operating income in 2025 was -$13.08 million, based on the following breakdown:
  • Total Gross Profit: $298.17 million
  • Total Operating Expenses: $311.25 million

Over the last 6 years, GeneDx's total revenue changed from $196.17 million in 2019 to $427.54 million in 2025, a change of 117.9%.

GeneDx's total liabilities were at $215.53 million at the end of 2025, a 23.8% increase from 2024, and a 12.8% decrease since 2020.

In the past 5 years, GeneDx's cash and equivalents has ranged from $85.21 million in 2024 to $400.57 million in 2021, and is currently $105.00 million as of their latest financial filing in 2025.

Over the last 6 years, GeneDx's book value per share changed from 0.00 in 2019 to 10.66 in 2025, a change of 1,066.2%.


Related Companies

Financial statements for NASDAQ:WGS last updated on 8/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel